Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01179113 · ClinicalTrials.gov registry record · Phase 4
Esmolol Infusion During Laminectomy: Effect on Quality of Recovery
A Phase 4 study, sponsored by Cedars-Sinai Medical Center.
- Terminated
- Registry status
- Phase 4
- Development phase
- 33
- Enrollment target
NCT01179113: Clinical Trial Phase 4 study, sponsored by Cedars-Sinai Medical Center.
NCT01179113 is a Phase 4 study that was terminated before completion, run by Cedars-Sinai Medical Center. The registered enrollment target is 33 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (94% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01179113, a Phase 4 study, was terminated before completion, sponsored by Cedars-Sinai Medical Center.
- TERMINATED
- Registry status
- Phase 4
- Development phase
- 33 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the effects of esmolol, a drug which is commonly administered during surgery to help control blood pressure and heart rate, on postoperative pain levels and requirements for pain medication.
Primary Outcome
Verbal Rating Scale goes from 0 to 10, where: 0 indicates= No pain" and 10 indicates= The worst possible pain The information was be recorded by study staff and data obtained from patient and patient charts from post-anesthesia care unit (PACU) stay
Interventions
- DRUG Saline
- DRUG Esmolol
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 33 participants |
| Start Date | 2011-06 |
| Est. Completion | 2015-05 |
| Phase | Phase 4 |
Why NCT01179113 stopped before completion
NCT01179113 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 33 participants, a relatively small participant target, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (94% lower).
The record links to 0 conditions, and to 2 interventions - of which Saline is the first listed.
NCT01179113 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01179113 about?
NCT01179113 is a clinical study titled "Esmolol Infusion During Laminectomy: Effect on Quality of Recovery". The purpose of this study is to evaluate the effects of esmolol, a drug which is commonly administered during surgery to help control blood pressure and heart rate, on postoperative pain levels and requirements for pain medication.
What is the current status of trial NCT01179113?
This trial is currently terminated. It is a Phase 4 study. The enrollment target is 33 participants. The study started on 2011-06. Estimated completion is 2015-05.
What interventions are being tested in trial NCT01179113?
The interventions under investigation include: Saline (DRUG), Esmolol (DRUG).
Who is sponsoring clinical trial NCT01179113?
This trial is sponsored by Cedars-Sinai Medical Center, which has 339 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01179113's enrollment target sits among peer trials
33 1528th of 2000 higher than 467 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02861898 · 33 participants · Phase 1
Super-selective Intra-arterial Repeated Infusion of Cetuximab for the Treatment of Newly Diagnosed Glioblastoma
- NCT04871607 · 33 participants · Phase 2
Yttrium-90 Labeled Anti-CD25 Monoclonal Antibody Combined With BEAM Chemotherapy Conditioning for the Treatment of Primary Refractory or Relapsed Hodgkin Lymphoma
- NCT05071937 · 33 participants · Phase 2
ZEN003694 Combined With Talazoparib in Patients With Recurrent Ovarian Cancer
- NCT05168618 · 33 participants · Phase 2
Cabozantinib and Atezolizumab for the Treatment of Metastatic Castration-Resistant Prostate Cancer, The AtezoCab Trial
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia